A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

The purpose of this study is:

1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD); 2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE). 3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD 4. to find possible predispose to MDD 5. to explore the DNA methylation status in depression;

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depression Behavior Behavioral Symptoms Depression Secondary to Other Disease

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Kunming Medical College

Kunming, Yunnan, 650031, China

About this study

to explore the pathology of depression
to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

DSM-IV Major Depression or Dysthymia
Age 18-65
Physically healthy
Drug-free

Exclusion criteria

Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
History of Psychosis or Epilepsy
Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
Bipolar I
Need for wash-out from effective treatment in order to participate
Pregnant
High suicide risk
Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Treatment and study plan

Escitalopram

Drug

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Primary outcomes

change of fMRI after medication

Time frame: baseline, 4 weeks, 8 weeks

Sponsors and collaborators

Lead sponsor

Kunming Medical University

Other

Collaborators

Chinese Academy of Sciences

Registry information

Important dates

Study start: 2008
Primary completion: 2011
Study completion: 2011
First posted: Jun 23, 2008
Registry last updated: Sep 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed